---
title: "Ankur Drugs & Pharma Ltd (ANKURDRUGS) — Share Price, Financials & Analysis"
symbol: "ANKURDRUGS"
company: "Ankur Drugs & Pharma Ltd"
canonical: "https://tapetide.com/stocks/ANKURDRUGS"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T18:39:12.299Z"
---

# Ankur Drugs & Pharma Ltd (ANKURDRUGS)

Canonical page: https://tapetide.com/stocks/ANKURDRUGS

## Company

- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** ankurdrugs.com

## About

Ankur Drugs & Pharma Limited, incorporated in India, Listed on the Bombay Stock  exchange Limited, and National Stock Exchange Limited, the company is engaged in Pharmaceutical Formulations

## Latest Price

## Key Insights

### Strengths

- Company has reduced debt.
- Stock is trading at 0.03 times its book value

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -16.5% over past five years.
- Company has a low return on equity of -17.1% over last 3 years.
- Company might be capitalizing the interest cost
- Debtor days have increased from 37.4 to 76.5 days.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | -151% | — | — |
| revenue growth | -82% | -46% | -17% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 14.27 | 16.74 | 14.29 | 13.6 | 12.62 | 13.87 | 13.04 | 11.03 | 11.08 | 12.71 | 14.43 | 14.78 |
| Expenses | 15.36 | 18.11 | 14.83 | 15.59 | 13.01 | 16.24 | 14.06 | 11.34 | 10.09 | 16.35 | 15.82 | 15.04 |
| Operating Profit | -1.09 | -1.37 | -0.54 | -1.99 | -0.39 | -2.37 | -1.02 | -0.31 | 0.99 | -3.64 | -1.39 | -0.26 |
| OPM % | -7.64 | -8.18 | -3.78 | -14.63 | -3.09 | -17.09 | -7.82 | -2.81 | 8.94 | -28.64 | -9.63 | -1.76 |
| Other Income | 1.11 | 1.1 | 1.14 | 2.66 | 1.4 | 1.35 | 1.32 | 1.03 | 1.11 | 1.12 | 1.11 | 2.06 |
| Interest | 0.32 | 0.23 | 0.27 | 0.48 | 0.19 | 0.22 | 0.2 | 0.45 | 0.14 | 0.25 | 0.17 | 0.64 |
| Depreciation | 0.17 | 0.18 | 0.17 | 0.26 | 0.19 | 0.18 | 0.29 | 0.11 | 0.18 | 0.24 | 0.22 | -0.11 |
| Profit before tax | -0.47 | -0.68 | 0.16 | -0.07 | 0.63 | -1.42 | -0.19 | 0.16 | 1.78 | -3.01 | -0.67 | 1.27 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -0.47 | -0.68 | 0.16 | -0.07 | 0.63 | -1.42 | -0.19 | 0.16 | 1.78 | -3.01 | -0.67 | 1.27 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 135 | 373 | 674 | 965 | 1067 | 825 | 151 |
| Expenses | 113 | 315 | 567 | 833 | 860 | 690 | 176 |
| Operating Profit | 22 | 58 | 107 | 132 | 207 | 135 | -25 |
| OPM % | 16 | 16 | 16 | 14 | 19 | 16 | -16 |
| Other Income | 0 | 0 | 2 | 2 | 20 | 0 | -144 |
| Interest | 4 | 13 | 25 | 54 | 81 | 121 | 58 |
| Depreciation | 2 | 6 | 8 | 21 | 27 | 61 | 61 |
| Profit before tax | 15 | 39 | 75 | 59 | 120 | -47 | -288 |
| Tax % | 9 | 17 | 15 | 37 | 28 | 47 | 7 |
| Net Profit | 14 | 33 | 64 | 37 | 86 | -69 | -307 |
| EPS in Rs | — | 31.01 | 50 | 19.95 | 44.56 | -35.58 | -158.98 |
| Dividend Payout % | 10 | 6 | 4 | 11 | 5 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 10 | 11 | 13 | 19 | 19 | 19 | 19 |
| Reserves | 19 | 103 | 207 | 253 | 338 | 269 | 219 |
| Borrowings | 111 | 352 | 618 | 745 | 950 | 1157 | 857 |
| Other Liabilities | 16 | 40 | 62 | 118 | 566 | 334 | 434 |
| Total Liabilities | 156 | 505 | 900 | 1135 | 1873 | 1779 | 1529 |
| Fixed Assets | 33 | 112 | 204 | 346 | 704 | 1220 | 1159 |
| CWIP | 66 | 245 | 331 | 266 | 786 | 285 | 266 |
| Investments | 0 | 0 | 5 | 4 | 0 | 0 | 0 |
| Other Assets | 58 | 148 | 359 | 519 | 383 | 275 | 103 |
| Total Assets | 156 | 505 | 900 | 1135 | 1873 | 1779 | 1529 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 8 | 23 | 22 | 42 | 844 | -41 | 3 |
| Cash from Investing Activity | -59 | -188 | -191 | -94 | -938 | -92 | 24 |
| Cash from Financing Activity | 53 | 165 | 226 | 9 | 88 | 130 | -27 |
| Net Cash Flow | 1 | 0 | 56 | -43 | -6 | -2 | 0 |
| Free Cash Flow | -52 | -165 | -165 | -55 | -61 | -117 | 11 |
| CFO/OP | 38 | 45 | 29 | 36 | 416 | -26 | -18 |

### Ratios

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 76 | 75 | 89 | 106 | 19 | 17 | 77 |
| Inventory Days | 86 | 77 | 83 | 105 | 120 | 98 | 57 |
| Days Payable | 19 | 31 | 24 | 28 | 207 | 85 | 478 |
| Cash Conversion Cycle | 144 | 121 | 148 | 183 | -68 | 29 | -344 |
| Working Capital Days | 119 | 109 | 134 | 154 | -67 | -14 | -722 |
| ROCE % | — | 17 | 15 | 12 | 17 | 5 | -7 |

## Shareholding Pattern

### annual

| Category | Mar 2017 | Mar 2018 | Jun 2018 |
| --- | --- | --- | --- |
| Promoters | 35.77% | 35.77% | 35.77% |
| FIIs | 0.26% | 0% | 0% |
| DIIs | 1.98% | 2.24% | 2.24% |
| Public | 61.98% | 61.98% | 61.98% |
| No. of Shareholders | 20744 | 20670 | 20666 |

### Quarterly

| Category | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 35.77% | 35.77% | 35.77% | 35.77% | 35.77% | 35.77% | 35.77% | 35.77% | 35.77% |
| FIIs | 0.26% | 0% | 0.26% | 0.26% | 0.26% | 0.26% | 0.26% | 0% | 0% |
| DIIs | 1.98% | 2.24% | 1.98% | 1.98% | 1.98% | 1.98% | 1.98% | 2.24% | 2.24% |
| Public | 61.98% | 61.99% | 61.98% | 61.98% | 61.98% | 61.98% | 61.98% | 61.98% | 61.98% |
| No. of Shareholders | 20755 | 20760 | 20751 | 20744 | 20743 | 20735 | 20662 | 20670 | 20666 |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| — | [Standalone Audited Financial Results For The Quarter And Year Ended 31.03.2018 - Re Submission. 29 May 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/5/575993b4-5536-4a49-9d48-5ac739e3986c.pdf) |
| — | [Board Meeting-Outcome of Board Meeting 28 May 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/5/b476d281-8a07-4f44-9d15-860656d5b7ce.pdf) |
| — | [Standalone Audited Financial Results For The Quarter And Year Ended 31St March, 2018 28 May 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/5/c6889a9a-f360-4a4c-9ac1-fd640294cd1b.pdf) |
| — | [Board Meeting On 28Th May, 2018 At 2.00 P.M. 17 May 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/5/84c17eda-8afd-4fd1-b515-9124966121de.pdf) |
| — | [Board Meeting-Closure of Trading Window 17 May 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/5/4d92b4c6-9203-4661-8b2f-e32c572ea618.pdf) |
| — | [Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 27 Apr 2017](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=FD7405BE_12AF_4020_A5AE_B6017170C713_174723.pdf) |
| — | [Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 27 Apr 2017](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/4/FD7405BE_12AF_4020_A5AE_B6017170C713_174723.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2011 from nse](https://archives.nseindia.com/annual_reports/AR_ANKURDRUGS_2010_2011_15062012100830.zip) |
| from nse | [Annual Report 2010 from nse](https://archives.nseindia.com/annual_reports/AR_ANKURDRUGS_2009_2010_13092010120000.zip) |
| from bse | [Annual Report 2012 from bse](https://www.bseindia.com/bseplus/AnnualReport/531683/5316830312.pdf) |
| from bse | [Annual Report 2011 from bse](https://www.bseindia.com/bseplus/AnnualReport/531683/5316830311.pdf) |
| from bse | [Annual Report 2010 from bse](https://www.bseindia.com/bseplus/AnnualReport/531683/5316830310.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:39:12.299Z.